The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome
Ain Shams University
60 participants
Apr 1, 2025
INTERVENTIONAL
Conditions
Summary
Long-term glucocorticoids therapy is associated with various complications, including decreased bone strength (Glucocorticoid-induced osteoporosis) and an increased risk of fracture. Vitamin K2 has been recently deemed appreciable as a topic of research as it plays a pivotal role in maintenance of the bone strength, and it has been proved to have a positive impact on the bone metabolism. This study examines the impact of oral vitamin K2 supplementation on bone metabolism in pediatric patients with nephrotic syndrome on long-term steroid therapy, offering valuable therapeutic insights
Eligibility
Inclusion Criteria2
- Nephrotic patients under 16 years of age of both genders who were treated with GC for the first time. GC treatment was initiated at a dose of 2 mg/kg/day prednisolone with gradual dose reduction.
- All patients have been on glucocorticoid therapy for more than 6 months. All patients have sufficient vitamin D level 30 ng/ml (75 nmol/L) or above.
Exclusion Criteria6
- Patients with impaired kidney functions.
- Non-compliant patients on medications or vitamin supplements.
- Diseases that affect fat-soluable vitamins absorption such as gallbladder or biliary disease, cystic fibrosis, celiac disease, etc.
- History of vitamin K-related disorders as bleeding disorders, osteomalacia , etc.
- History of bone fracture before the study.
- Any nephrotic syndrome with identified genetic causes.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral vitamin K2 supplementation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07206537